Human antibodies that bind tnf.alpha.
CA 2722378 C · Owner: Amgen Fremont Inc. · Inventors: Green, Larry; Kucherlapati, Raju; Jakobovits, Aya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to human antibodies that specifically bind human TNF.alpha. or an antigen-binding portion of such an antibody. In some embodiments, the , antibodies comprise a human IgG2 heavy chain and a human kappa light chain. The , antibodies of the present invention are capable of reducing the binding of human TNF.alpha. to a , human TNF.alpha. receptor. Embodiments include antibodies and antigen-binding portions thereof , that bind human TNF.alpha. with a KD of 1.89-8.06 X 10 -10 M and/or a KA of 1.2-5.3 X 10 9 M-1, and that may further bind TNF.alpha. with a ka of 1.6-2.9 x 10 6 M-1S-1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 3, 1997 and granted February 3, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 3, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 3, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.